Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Squamous Cell 1Melanoma 1Lymphoma 1Liver Neoplasms 1Hodgkin Disease 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

pembrolizumab 38Nivolumab 24atezolizumab 10Ipilimumab 7Carboplatin 6avelumab 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Docetaxel 5Cyclophosphamide 5fludarabine 4cabozantinib 4Specimen Handling 4Pemetrexed 4regorafenib 3Interleukin-2 3Gemcitabine 3130-nm albumin-bound paclitaxel 3spartalizumab 2lenvatinib 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Immune Checkpoint Inhibitors 2Cisplatin 2Biopsy 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × advexin × Thoracic × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡